Clopidogrel is a medication that is used to decrease the ability of platelets to form blood
The theory has been proposed that, in patients with coronary artery disease or stroke,
increased platelet function after discontinuation of clopidogrel therapy is associated with
an increased clotting risk. However, this theory has never been rigorously tested.
The goal of this research is to determine whether discontinuation of clopidogrel results in
increased platelet function.
In this study, we will address the question: does discontinuation of clopidogrel result in
platelet hyperreactivity? We will perform a double-blind, placebo-controlled, crossover
study in normal subjects, in whom platelet reactivity will be measured before clopidogrel or
placebo, during clopidogrel or placebo, and at various time points after discontinuation of
clopidogrel or placebo. The dose of clopidogrel will be the standard, FDA-approved dose: 75
mg daily. All subjects will be treated with aspirin 81 mg daily throughout the 57 days of
study assessment in both the clopidogrel arm and the placebo arm, because the clinically
relevant question is: in patients who remain on aspirin, does discontinuation of clopidogrel
result in platelet hyperreactivity?
- Must be a normal healthy subject
- Must be between 21-70 years old
- Must be able to take aspirin and clopidogrel.
- Must be able to have blood drawn 16 times over approximately 3 months.
- Subject who is currently taking aspirin or another anti-platelet drug such as
clopidogrel. Subject must be free of these medications for 10 days before enrolling
in this study.
- Subject who is currently taking a non-steroidal anti-inflammatory drug such as
ibuprofen or naproxen. Subject must be free of these medications for 3 days before
enrolling in this study.
- Subject who is currently taking medications for depression or medications that lower
blood pressure or lower blood sugar.
- Subject who are pregnant or may become pregnant during the study or who is breast
- Subject with a known allergy to aspirin or clopidogrel.
- Cigarette smoking or use of other nicotine product.
- Subject with a history of any of the following: coronary artery disease; stroke;
bleeding disorder; ongoing bleeding; previous life-threatening hemorrhage; stomach
ulcers; gastrointestinal bleeding within the past 1 month; major surgery within the
past 1 month; minor surgery within the past 2 weeks; or platelet transfusion within
the past 7 days.
- Subject with a blood count, measured on the pre-study drug blood sample, that is not
in the normal range.
- Subject who is enrolled in another clinical trial of an investigational drug.
Alan D. Michelson, M.D.
University of Massachusetts Medical School
Marsha L Fox, MS, RN
Worcester, Massachusetts 01655
Marsha L. Fox, MS, RN
Site Status: Recruiting